Comparative Efficacy of Goserelin vs. Leuprolide in Advanced Prostate Cancer in Patients Undergoing Androgen Deprivation Therapy

Abstract

ABSTRACT Objectives: To determine the efficacy (achievement of castrate testosterone level at six months) of LHRH agonist therapy with different agonists, i.e., Leuprolide vs. Goserelin. Study Design: Quasi-experimental study. Place and Duration of Study: Radiation Oncology Department, Combined Military Hospital Rawalpindi Pakistan, from Jan to Oct 2020. Methodology: One hundred and seventy-eight patients (n=178) having histopathologically confirmed prostate adenocarcinoma, aged 60 to 80 years, with eastern cooperative oncology group (ECOG) performance status ≤2, men with advanced prostate cancer were randomly assigned to receive different treatment, group 1(89) patients received Goserelin. 3.6mg vs group 2(89) received Leuprolide 7.5mg. The study achieved 100 % accrual in the initial 2.5 months from the start of the study. Each agent was injected intramuscularly six times every 28 days for six injections. The percentage of men whose serum testosterone concentrations fell to and remained at or below castrate levels was the primary endpoint. Results: Analysis was made on 178 patients in this study. No statistically significant difference was observed between the two groups in terms of achievement of castration levels of testosterone (Leuprolide 98.9% vs. Goserline 88.7%, respectively: p=0.126) from baseline to 6 months. The chi-square test was applied to the outcome in both groups, and results were found to be insignificant statistically (p=0.126). Conclusion: In this study, no significant difference was determined between groups in attaining and maintaining castration levels of serum testosterone at six months.

Keywords

• Advanced prostate cancer
• castration
• Goserelin
• Leuprolide
• CAB complete androgen blockade
• ADT androgen deprivation therapy